Thermal inactivation of protective antigen of Bacillus anthracis and its prevention by polyol osmolytes

Biochemical and Biophysical Research Communications
Samer SinghRakesh Bhatnagar

Abstract

Protective antigen (PA) of Bacillus anthracis is the main immunogen of all anthrax vaccines. It is a highly thermolabile molecule and loses its activity rapidly when exposed to higher temperatures. Earlier some cosolvents had been used to stabilize PA with variable success but no study has been done to find out the primary cause of PA thermal inactivation. This study aims at elucidating the predominant cause of thermal inactivation of PA in order to develop more effective strategies for its thermostabilization. The prime cause for the loss of biological activity of PA at high temperature was its aggregation and an inverse correlation between PA activity and its aggregation on heating was observed. Inactivation of the protein by autolysis did not occur. This paper reports the use of a series of polyol osmolytes to stabilize PA. Different polyols stabilized PA to a different extent against thermal inactivation in a concentration dependent manner, with glycerol stabilizing to the maximum extent. Addition of NaCl to glycerol solution further enhanced the thermal stability of PA. An increase in the T(1/2) value, the temperature at which 50% of the activity is retained during short-term incubation, of more than 20 degrees C was obser...Continue Reading

References

May 3, 1988·Biochemistry·C N Pace, G R Grimsley
Jan 1, 1974·International Journal of Peptide and Protein Research·S Y Gerlsma, E R Stuur
Jan 1, 1972·International Journal of Peptide and Protein Research·S Y Gerlsma, E R Stuur
Dec 1, 1972·Archives of Biochemistry and Biophysics·R P Frigon, J C Lee
Jul 1, 1983·Archives of Biochemistry and Biophysics·T Arakawa, S N Timasheff
Sep 24, 1982·Science·P H YanceyG N Somero
Sep 27, 1995·Biochimica Et Biophysica Acta·C O Fágáin
Feb 6, 1995·Biochemical and Biophysical Research Communications·K H BaeS M Byun
Jan 1, 1994·Pharmaceutical Research·H R CostantinoA M Klibanov
Aug 10, 1993·Biochemistry·L M Mayr, F X Schmid
Feb 7, 1997·The Journal of Biological Chemistry·R W Ruddon, E Bedows
Apr 1, 1997·Protein Science : a Publication of the Protein Society·K J Frye, C A Royer
Feb 28, 1997·Biophysical Chemistry·G Xie, S N Timasheff
Mar 21, 1998·Biochimica Et Biophysica Acta·B M GorovitsP M Horowitz
Apr 16, 1998·Protein Science : a Publication of the Protein Society·G I MakhatadzeS T Thomas
May 1, 1997·Pharmaceutical Development and Technology·M Katakam, A K Banga
Jul 17, 1998·Current Opinion in Biotechnology·N Smirnoff
Aug 5, 1998·Proceedings of the National Academy of Sciences of the United States of America·Y QuD W Bolen
May 7, 1999·Journal of Pharmaceutical Sciences·M C Lai, E M Topp
Jul 30, 1999·Protein Expression and Purification·P GuptaR Bhatnagar
Aug 26, 1999·International Journal of Pharmaceutics·W Wang
Mar 10, 2001·Microbiology and Molecular Biology Reviews : MMBR·C Vieille, G J Zeikus
May 1, 2001·Biochemical and Biophysical Research Communications·V ChauhanR Bhatnagar
Jun 8, 2001·The International Journal of Biochemistry & Cell Biology·F MengH Zhou
Aug 15, 2001·Journal of Molecular Biology·D W Bolen, I V Baskakov
Jan 25, 2002·Archives of Microbiology·Yuri A Trotsenko, Valentina N Khmelenina
Sep 5, 2002·Biochemical and Biophysical Research Communications·Samer SinghRakesh Bhatnagar
Sep 27, 2002·Current Opinion in Biotechnology·Bertus van den Burg, Vincent G H Eijsink
Mar 17, 2004·Biochemical and Biophysical Research Communications·Samer SinghRakesh Bhatnagar

❮ Previous
Next ❯

Citations

Mar 3, 2012·Molecular Pharmaceutics·L K PetersenB Narasimhan
Dec 15, 2010·Clinical and Vaccine Immunology : CVI·Juan Castelán-VegaJuan Arciniega
Nov 10, 2012·Biologicals : Journal of the International Association of Biological Standardization·Rocío I Domínguez-CastilloJuan L Arciniega
Jun 12, 2012·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Ashok GanesanBarry D Moore
Jun 15, 2011·Biologicals : Journal of the International Association of Biological Standardization·Alicia Jiménez-AlbertoJuan Arciniega
Aug 9, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Kevin J McHughAna Jaklenec
Mar 18, 2008·Plant Physiology and Biochemistry : PPB·Martina Ortbauer, Marianne Popp
Feb 26, 2016·Nature Communications·Ashok GanesanJoost Schymkowitz
Feb 24, 2010·Applied Microbiology and Biotechnology·Nagesh K TripathiP V Lakshmana Rao
Oct 3, 2018·Human Vaccines & Immunotherapeutics·Tauheed HasanLaishram Rajendrakumar Singh
Sep 29, 2005·The Journal of Biological Chemistry·Gil ZomberEytan Elhanany
Aug 28, 2020·Journal of Ethnopharmacology·Rajinder KaurSamer Singh
Jul 31, 2020·Expert Opinion on Biological Therapy·Manish ManishRakesh Bhatnagar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.